HSCS: financial statements from SEC — TradeAlmanac

HSCS

HeartSciences Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024
Revenue	0	2,419	1,900	0	—	—
Cost of revenue	0	1,008	760	0	—	—
Gross profit	0	1,411	1,140	0	—	—
Research and development	638,575	727,026	997,206	1m	1m	1m
Selling, general and administrative	1m	1m	878,053	1m	786,068	850,736
Operating expenses	2m	2m	2m	2m	2m	2m
Operating income	−2m	−2m	−2m	−2m	−2m	−2m
Net income	−2m	−2m	−2m	−3m	−2m	−2m
Earnings per share	−0.63	−0.85	−1.58	−2.57	−2.27	−2.64
Earnings per share, diluted	—	−0.85	−1.58	−2.57	−2.27	−2.64
Weighted average shares	3m	3m	1m	986,057	917,445	777,746
Weighted average shares, diluted	—	3m	1m	986,057	917,445	777,746

Balance sheet

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024	Apr 30, 2024
Cash and equivalents	3m	2m	3m	1m	3m	4m	4m	6m
Receivables	0	—

Cash flow

Metric	Jul 31, 2025	Jul 31, 2024
Operating cash flow	−2m	−2m
Depreciation and amortisation	7,111	11,864
Share-based compensation	174,558	54,554
Investing cash flow	−814	−833
Financing cash flow	4m	551,683

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)